Clinical Considerations for Targeted Therapies Across Multiple Tumor Types - a podcast by ReachMD

CME credits: 0.25

Valid until: 21-08-2021

Claim your CME credit at https://reachmd.com/programs/cme/clinical-considerations-targeted-therapies-across-multiple-tumors/11752/

Anti-HER2 therapy is well established as a first-line approach for many patients with metastatic breast cancer. HER2 has now been identified as an oncogenic driver across multiple malignancies, including non-small cell lung cancer, colorectal cancer, and gastric cancer. Dr. Sara A. Hurvitz and Dr. Jacob M. Sands discuss the rationale for incorporating the various anti-HER2 therapies in the clinic, and with the use of 3D animation address the emergence of anti-HER2 treatment resistance and novel approaches to overcome that resistance.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD